A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

BACKGROUND: Long-acting muscarinic antagonist/long-acting β(2)-agonist combinations are recommended for patients whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy and safety of glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Reisner, Colin, Fabbri, Leonardo M., Kerwin, Edward M., Fogarty, Charles, Spangenthal, Selwyn, Rabe, Klaus F., Ferguson, Gary T., Martinez, Fernando J., Donohue, James F., Darken, Patrick, St. Rose, Earl, Orevillo, Chad, Strom, Shannon, Fischer, Tracy, Golden, Michael, Dwivedi, Sarvajna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216561/
https://www.ncbi.nlm.nih.gov/pubmed/28061907
http://dx.doi.org/10.1186/s12931-016-0491-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216561/
https://www.ncbi.nlm.nih.gov/pubmed/28061907
http://dx.doi.org/10.1186/s12931-016-0491-8

Ejemplares similares